PUBLISHER: The Business Research Company | PRODUCT CODE: 1750992
PUBLISHER: The Business Research Company | PRODUCT CODE: 1750992
Esketamine is a fast-acting anesthetic and antidepressant derived from ketamine, known for its NMDA receptor antagonist properties. It is primarily used to treat treatment-resistant depression and major depressive disorder with suicidal ideation, administered as a nasal spray under medical supervision.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main forms of esketamine include oral medications, injections, nasal sprays, and others. Oral medications consist of pills or tablets containing esketamine, which are taken orally to treat conditions such as depression. Its indications cover major depressive disorder, chronic pain, post-traumatic stress disorder, and anxiety disorders. The patient categories include adults, pediatrics, and geriatric patients. Esketamine is applied for general anesthesia and treatment-resistant depression, and it is distributed through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies.
The esketamine market research report is one of a series of new reports from The Business Research Company that provides esketamine market statistics, including the esketamine industry global market size, regional shares, competitors with the esketamine market share, detailed esketamine market segments, market trends, and opportunities, and any further data you may need to thrive in the esketamine industry. This esketamine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The esketamine market size has grown rapidly in recent years. It will grow from$1.37 billion in 2024 to $1.52 billion in 2025 at a compound annual growth rate (CAGR) of 11.2%. The growth during the historic period can be attributed to a growing number of patients, the rising prevalence of mental health issues globally, improved awareness of the disease state, increased demand for innovative therapeutic options, and favorable regulatory approvals.
The esketamine market size is expected to see rapid growth in the next few years. It will grow to$2.31 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. The growth during the forecast period can be attributed to the rising prevalence of treatment-resistant depression, increased investment in research and development programs, demand for smart healthcare infrastructure, the growing adoption of telehealth services, and the increasing acceptance of esketamine as an effective treatment. Key trends expected during this period include partnerships between biotech companies and mental health organizations, the use of robotics in healthcare applications, personalized medicine strategies, the rise of sensor-based devices, and the potential for combination therapies.
The growing prevalence of treatment-resistant depression (TRD) is expected to drive the expansion of the esketamine market in the coming years. TRD refers to depression that does not improve despite trying at least two different antidepressant medications at appropriate doses for a sufficient duration. The rise in treatment-resistant depression is largely due to the limited effectiveness of conventional antidepressants, which leads to prolonged and recurring depressive episodes. Esketamine offers a promising solution for TRD by providing a rapid-acting mechanism that targets NMDA receptors, offering relief to patients who do not respond to traditional antidepressants. For example, in September 2023, the National Institute of Mental Health (NIMH) in the U.S. reported that approximately 30% of individuals with major depressive disorder in the U.S. are resistant to standard treatments. Consequently, the increasing incidence of treatment-resistant depression is fueling the growth of the esketamine market.
Esketamine's approval as a monotherapy for treatment-resistant depression marks a breakthrough in TRD treatment. Major companies in the esketamine market are focusing on developing advanced solutions such as monotherapy, which involves using a single drug to manage a condition, rather than combining multiple therapies. In January 2025, Johnson & Johnson, a U.S.-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Supported by clinical trial data, the approval showed that SPRAVATO could rapidly alleviate depressive symptoms, with significant improvements occurring within 24 hours. This breakthrough provides a vital option for the 30% of individuals who do not respond to traditional antidepressants, eliminating the need for additional oral medications. While SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to manage potential side effects. This milestone represents a major advancement in TRD treatment, offering renewed hope for better patient outcomes.
In April 2024, Celon Pharma S.A., a Poland-based pharmaceutical company, partnered with Tang Capital Management LLC to create Novohale Therapeutics, LLC. This collaboration is focused on advancing the development of Falkieri, an esketamine dry powder inhalation product, into global Phase 3 clinical trials for bipolar depression. Tang Capital Management LLC, a U.S.-based company specializing in life sciences and biotechnology, is working with Celon Pharma to bring this innovative treatment to market.
Major players in the esketamine market are Cigna Corporation, Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Horizon Therapeutics plc, Hikma Pharmaceuticals plc, Alkem Laboratories Limited, Cerecor Inc., Celon Pharma S.A., Nortec Quimica S.A., XWPharma Ltd., Seqens Group, SynZeal Research Pvt. Ltd., Arevipharma GmbH, Sage Therapeutics Inc., Supriya Lifescience Ltd., Clexio Biosciences Ltd., Maithri Drugs Pvt. Ltd., and VistaGen Therapeutics Inc.
North America was the largest region in the esketamine market in 2024. The regions covered in esketamine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the esketamine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The esketamine market consists of sales of products including spravato, and esketamine injectable formulations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Esketamine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on esketamine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for esketamine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The esketamine market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.